Trending...
- California: Governor Newsom responds to DOGE's dismantling of AmeriCorps: 'Middle finger to volunteers. We will sue'
- 100 days after the fires: California and Los Angeles rebuild, recover, and rise together
- California: Governor Newsom announces appointments 4.18.25
MONTREAL, Nov. 20, 2024 ~ Thryv Therapeutics Inc., a clinical-stage biotechnology company, has recently announced the appointment of Dr. Amy Sehnert as their new Chief Medical Officer (CMO). With her extensive experience in pediatric cardiology and her background in innovative biotech companies, Dr. Sehnert will lead the clinical development and strategy for Thryv Therapeutics' expanding cardiometabolic product portfolio.
Dr. Sehnert brings over 20 years of experience as a serial and founding medical lead at various biotech companies, where she has introduced precision diagnostics and therapeutics to the clinic. Most recently, she served as Vice President and Global Program Lead for cardiovascular assets at Bristol Myers Squibb (BMS). During her time at BMS, she played a crucial role in the development and approval of Camzyos®, a groundbreaking treatment for hypertrophic cardiomyopathy (HCM). Her contributions to this development ultimately led to BMS's acquisition of MyoKardia, Inc. for $14 billion in 2020.
Expressing her excitement about joining Thryv Therapeutics, Dr. Sehnert said, "I am thrilled to join Thryv Therapeutics at such an important time in the company's journey. Thryv Therapeutics' cutting-edge approach to cardiovascular diseases aligns with my passion for advancing precision medicine, and I look forward to working with the team to deliver transformative therapies to patients worldwide."
More on The Californer
Aside from her work in cardiovascular diseases, Dr. Sehnert has also made significant contributions in other fields of medicine such as maternal-fetal health, oncology, and genomics. She was one of the early pioneers in non-invasive prenatal testing (NIPT) and cell-free DNA applications that are now widely used in clinical settings.
Dr. Sehnert holds a Doctor of Medicine degree from the University of Minnesota and completed her residency in Pediatrics at the University of Colorado. She also completed a fellowship in Pediatric Cardiology at UCSF and has held faculty appointments at both UCSF and Stanford University. In 2022, she was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco. She has co-authored over 60 peer-reviewed publications and is considered an internationally recognized expert in her field.
Thryv Therapeutics' CEO, Paul F. Truex, expressed his excitement about Dr. Sehnert joining the team, saying, "On behalf of Thryv Therapeutics, I am excited to welcome Amy to the team. Her extensive experience in designing and executing late-stage clinical trials for genetic and broader cardiovascular diseases, along with her leadership qualities, will be invaluable as we enter the next phase of clinical development for our SGK1 portfolio."
More on The Californer
Dr. Philip Sager, Thryv Therapeutics' founding Chief Medical Officer, will continue to provide strategic clinical and regulatory guidance as the company's portfolio advances into later stage clinical studies. Truex also expressed his gratitude for Dr. Sager's contributions to Thryv Therapeutics' portfolio thus far and his commitment to finding treatments for patient communities.
In conclusion, Thryv Therapeutics is excited to have Dr. Amy Sehnert join their team as their new Chief Medical Officer. With her expertise and experience in precision medicine and clinical development, she will play a crucial role in advancing Thryv Therapeutics' cardiometabolic product portfolio targeting serum glucocorticoid inducible kinase 1 (SGK1).
Dr. Sehnert brings over 20 years of experience as a serial and founding medical lead at various biotech companies, where she has introduced precision diagnostics and therapeutics to the clinic. Most recently, she served as Vice President and Global Program Lead for cardiovascular assets at Bristol Myers Squibb (BMS). During her time at BMS, she played a crucial role in the development and approval of Camzyos®, a groundbreaking treatment for hypertrophic cardiomyopathy (HCM). Her contributions to this development ultimately led to BMS's acquisition of MyoKardia, Inc. for $14 billion in 2020.
Expressing her excitement about joining Thryv Therapeutics, Dr. Sehnert said, "I am thrilled to join Thryv Therapeutics at such an important time in the company's journey. Thryv Therapeutics' cutting-edge approach to cardiovascular diseases aligns with my passion for advancing precision medicine, and I look forward to working with the team to deliver transformative therapies to patients worldwide."
More on The Californer
- Charleston, SC - ACSEC offers Rain Barrels Through Annual Program
- HAVAS CHICAGO APPOINTS FRANK DATTALO AS CHIEF CREATIVE OFFICER
- Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
- Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
- OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
Aside from her work in cardiovascular diseases, Dr. Sehnert has also made significant contributions in other fields of medicine such as maternal-fetal health, oncology, and genomics. She was one of the early pioneers in non-invasive prenatal testing (NIPT) and cell-free DNA applications that are now widely used in clinical settings.
Dr. Sehnert holds a Doctor of Medicine degree from the University of Minnesota and completed her residency in Pediatrics at the University of Colorado. She also completed a fellowship in Pediatric Cardiology at UCSF and has held faculty appointments at both UCSF and Stanford University. In 2022, she was recognized as one of the Most Influential Women in Business by the San Francisco Business Times and among the Top 25 Healthcare Technology Leaders of San Francisco. She has co-authored over 60 peer-reviewed publications and is considered an internationally recognized expert in her field.
Thryv Therapeutics' CEO, Paul F. Truex, expressed his excitement about Dr. Sehnert joining the team, saying, "On behalf of Thryv Therapeutics, I am excited to welcome Amy to the team. Her extensive experience in designing and executing late-stage clinical trials for genetic and broader cardiovascular diseases, along with her leadership qualities, will be invaluable as we enter the next phase of clinical development for our SGK1 portfolio."
More on The Californer
- UC Ventures Appoints Julie Chang as Managing Director of Investments
- MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
- New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY
- Armed With Purpose and Trained To Lead
- Introducing the Heart-Shaped Pearl Earrings — A Romantic New Addition from Sairahaz Jewelers
Dr. Philip Sager, Thryv Therapeutics' founding Chief Medical Officer, will continue to provide strategic clinical and regulatory guidance as the company's portfolio advances into later stage clinical studies. Truex also expressed his gratitude for Dr. Sager's contributions to Thryv Therapeutics' portfolio thus far and his commitment to finding treatments for patient communities.
In conclusion, Thryv Therapeutics is excited to have Dr. Amy Sehnert join their team as their new Chief Medical Officer. With her expertise and experience in precision medicine and clinical development, she will play a crucial role in advancing Thryv Therapeutics' cardiometabolic product portfolio targeting serum glucocorticoid inducible kinase 1 (SGK1).
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor Newsom's investment to prevent and prosecute organized retail crime yields 14,133 prosecution case referrals
- Long Beach Gears Up to Celebrate National Bike Month 2025
- Dreame Technology Expands US Footprint with New San Diego Location
- Pelican Reef Group Announces Grand Opening of New High Point Showroom – IHFC Building H-621 & Event April 27th, 2025
- PATH Honors Sayed Ali of Interpreters Unlimited For His Dedication to Fighting Homelessness
- FIELD MEDICAL ANNOUNCES FIRST-IN-HUMAN DATA FOR FOCAL PFA IN SCAR-RELATED VT AT HEART RHYTHM 2025 USA - English APAC - English USA - English
- NaturismRE Launches the 11 Levels of Naturism: A Groundbreaking Framework Guiding the Global Naturist Journey
- K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
- Startup Agency Launches Fractional Consulting for Founders
- The World's No.1 Superstar™ Walks Where Legends Rest: A Sacred Encounter in Rome Before the Pope's Passing
- Lafayette's Leila Douglah Wins 3rd Place in Sub-Zero, Wolf, and Cove Global Kitchen Design Contest
- Kitchen Exhaust Hood Cleaning in Orange County
- California: Governor Newsom announces appointments 4.22.25
- Coming Up on "Financial Freedom with Tom Hegna" Financial Expert Parker Faulkner
- California: PHOTOS: Governor Newsom, First Partner Siebel Newsom celebrate Earth Day with next generation of agricultural stewards
- Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025
- Flexi-View Lending Closes $20 Million Business Loan for Strategic Purchase in Frankfort, KY
- Kemeny, Ramp & Renaud, LLC Welcomes Prominent Trusts and Estates Attorney Gary B. Cornick to Its Firm
- DESERT BLOOM™ Makes a Bold Entrance, Kicking Fast Fashion Off Its High Horse with Earth Day Launch
- The Bancorp, Inc. (TBBK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit